Bayer's admission of 'mistake' underscores FDA's struggles

A Bayer admission that it "mistakingly" did not submit new risk information to the FDA on antibleeding drug Trasylol underscores the agency's struggle to get critical drug safety information out to the public. FDA had to replace a news release hours after it was issued to reflect new data.
You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory